Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Toshiaki Takakura"'
Autor:
Toshiaki Takakura, Hiroaki Akamatsu, Atsushi Washioka, Eriko Murakami, Ryota Shibaki, Toshio Shimizu, Yasuhiro Koh, Nobuyuki Yamamoto
Publikováno v:
Respirology Case Reports, Vol 12, Iss 9, Pp n/a-n/a (2024)
Abstract Several predictive factors of immune checkpoint inhibitor response have been reported, but there has not been sufficient exploration of which patients benefit from immune checkpoint inhibitor rechallenge. We report the case of a patient with
Externí odkaz:
https://doaj.org/article/0ae7b666526f4947868c9ccb401342a5
Autor:
Hideto Iguchi, Hiroaki Akamatsu, Yoshimitsu Hirai, Takahito Nakaya, Aya Fusamoto, Yumi Yata, Takahiro Nagai, Daiki Kitahara, Toshiaki Takakura, Yoshiharu Nishimura, Nobuyuki Yamamoto
Publikováno v:
Respirology Case Reports, Vol 12, Iss 8, Pp n/a-n/a (2024)
Abstract Neoadjuvant therapy with nivolumab improves event‐free survival (EFS) in patients with resectable non‐small cell lung cancer, and a pathological complete response is a predictor of longer EFS. We assessed metabolic responses using 18F‐
Externí odkaz:
https://doaj.org/article/eb56f627c8144471983a5a3c7440a73c
Autor:
Takahito Nakaya, Yoshimitsu Hirai, Hiroaki Akamatsu, Fumiyoshi Kojima, Hideto Iguchi, Aya Fusamoto, Yumi Yata, Takahiro Nagai, Daiki Kitahara, Toshiaki Takakura, Yoshiharu Nishimura, Nobuyuki Yamamoto
Publikováno v:
Respirology Case Reports, Vol 12, Iss 5, Pp n/a-n/a (2024)
Abstract The standard treatment for resectable non‐small cell lung cancer (NSCLC) located in the superior sulcus is neoadjuvant chemoradiotherapy followed by highly invasive resection. Based on the results of the CheckMate 816 trial, which showed a
Externí odkaz:
https://doaj.org/article/eb7e0e281ee44fe080e230f645403d1b
Autor:
Eriko Murakami, Hiroaki Akamatsu, Shunsuke Teraoka, Toshiaki Takakura, Eri Takase, Masanori Tanaka, Takahiro Kaki, Yuhei Harutani, Katsuyuki Furuta, Takeya Sugimoto, Ryota Shibaki, Daichi Fujimoto, Atsushi Hayata, Yuichi Ozawa, Masanori Nakanishi, Yasuhiro Koh, Toshio Shimokawa, Nobuyuki Yamamoto
Publikováno v:
Cancer Medicine, Vol 13, Iss 4, Pp n/a-n/a (2024)
Abstract Background Mannitol is exclusively recommended in the National Comprehensive Cancer Network guidelines for diuresis in cisplatin (CDDP)‐based chemotherapy. The utility of furosemide, a widely used and convenient diuretic, thus requires cla
Externí odkaz:
https://doaj.org/article/936934c8acbe4ec093a80de605ccb236
Autor:
Toshiaki Takakura, MD, Hiroaki Kanemura, MD, MPH, Kazuko Sakai, PhD, Kazuto Nishio, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Hidetoshi Hayashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 6, Pp 100523- (2023)
Resistance to ROS1 tyrosine kinase inhibitors is inevitable, but it has been unclear whether crizotinib might be effective after the development of entrectinib resistance. We here present a case of ROS1-rearranged NSCLC that responded to crizotinib a
Externí odkaz:
https://doaj.org/article/e7d70624992c46b5bea477f455c8785c
Autor:
Nahomi Tokudome, Shunsuke Teraoka, Ryota Shibaki, Eriko Murakami, Jun Oyanagi, Masanori Nakanishi, Yuhei Harutani, Nobuyuki Yamamoto, Toshiaki Takakura, Yuka Okuda, Takeya Sugimoto, Kouichi Sato, Masanori Tanaka, Yuichi Ozawa, Atsushi Hayata, Yuka Kitamura, Hiroaki Akamatsu, Yasuhiro Koh, Katsuyuki Furuta, Hiroki Ueda, Junya Fukuoka
Publikováno v:
Cancer Science
CD24, a heavily glycosylated glycosylphosphatidylinositol–anchored surface protein, inhibits phagocytosis as potently as CD47. The relationship between such anti‐phagocytic factors and the immune response with immune–checkpoint inhibitors (ICI)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc26129824c4689c6cb7258a8dc1b4b8
https://pubmed.ncbi.nlm.nih.gov/33084148
https://pubmed.ncbi.nlm.nih.gov/33084148
Autor:
Iguchi, Hideto1, Akamatsu, Hiroaki2 hiroakiakamatsu@gmail.com, Hirai, Yoshimitsu1, Nakaya, Takahito1, Fusamoto, Aya1, Yata, Yumi1, Nagai, Takahiro2, Kitahara, Daiki2, Takakura, Toshiaki2, Nishimura, Yoshiharu1, Yamamoto, Nobuyuki2
Publikováno v:
Respirology Case Reports. Aug2024, Vol. 12 Issue 8, p1-4. 4p.
Autor:
Takakura, Toshiaki1 (AUTHOR), Akamatsu, Hiroaki1 (AUTHOR) h-akamat@wakayama-med.ac.jp, Washioka, Atsushi1 (AUTHOR), Murakami, Eriko1 (AUTHOR), Shibaki, Ryota1 (AUTHOR), Shimizu, Toshio1 (AUTHOR), Koh, Yasuhiro1,2 (AUTHOR), Yamamoto, Nobuyuki1,2 (AUTHOR)
Publikováno v:
Respirology Case Reports. Sep2024, Vol. 12 Issue 9, p1-3. 3p.
Autor:
Nakaya, Takahito1 (AUTHOR), Hirai, Yoshimitsu1 (AUTHOR) mitsu@wakayama-med.ac.jp, Akamatsu, Hiroaki2 (AUTHOR), Kojima, Fumiyoshi3 (AUTHOR), Iguchi, Hideto1 (AUTHOR), Fusamoto, Aya1 (AUTHOR), Yata, Yumi1 (AUTHOR), Nagai, Takahiro2 (AUTHOR), Kitahara, Daiki2 (AUTHOR), Takakura, Toshiaki2 (AUTHOR), Nishimura, Yoshiharu1 (AUTHOR), Yamamoto, Nobuyuki2 (AUTHOR)
Publikováno v:
Respirology Case Reports. May2024, Vol. 12 Issue 5, p1-4. 4p.
Autor:
Murakami, Eriko1 (AUTHOR), Akamatsu, Hiroaki1 (AUTHOR) h‐akamat@wakayama‐med.ac.jp, Teraoka, Shunsuke1 (AUTHOR), Takakura, Toshiaki1 (AUTHOR), Takase, Eri1 (AUTHOR), Tanaka, Masanori1 (AUTHOR), Kaki, Takahiro1 (AUTHOR), Harutani, Yuhei1 (AUTHOR), Furuta, Katsuyuki1 (AUTHOR), Sugimoto, Takeya1 (AUTHOR), Shibaki, Ryota1 (AUTHOR), Fujimoto, Daichi1 (AUTHOR), Hayata, Atsushi1 (AUTHOR), Ozawa, Yuichi1 (AUTHOR), Nakanishi, Masanori1 (AUTHOR), Koh, Yasuhiro1,2 (AUTHOR), Shimokawa, Toshio3 (AUTHOR), Yamamoto, Nobuyuki1,2,3 (AUTHOR)
Publikováno v:
Cancer Medicine. Feb2024, Vol. 13 Issue 4, p1-8. 8p.